Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibody monotherapy (PD1) has led to favorable responses in advanced non-acral cutaneous melanoma among Caucasian populations; however, recent studies suggest that this therapy has limited efficacy in mucosal melanoma (MCM). Thus, advanced MCM...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Y., Namikawa, K., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., Fukushima, S., Saito, S., Takenouchi, T., Tanaka, R., Kato, H., Otsuka, A., Matsuya, T., Baba, N., Nagase, K., Inozume, T., Fujimoto, N., Kuwatsuka, Y., Onishi, M., Kaneko, T., Onuma, T., Umeda, Y., Ogata, D., Takahashi, A., Otsuka, M., Teramoto, Y., Yamazaki, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633880/
https://www.ncbi.nlm.nih.gov/pubmed/34839104
http://dx.doi.org/10.1016/j.esmoop.2021.100325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633880/
https://www.ncbi.nlm.nih.gov/pubmed/34839104
http://dx.doi.org/10.1016/j.esmoop.2021.100325

Ejemplares similares